JNK and IKKβ phosphorylation is reduced by glucocorticoids in adipose tissue from insulin-resistant rats

https://doi.org/10.1016/j.jsbmb.2014.09.024Get rights and content

Highlights

  • DEX rats have decreased PKB and increased IRS-1 serine phosphorylation in adipose tissue.

  • Adipose tissue from DEX rats has reduced JNK and IKKβ phosphorylation.

  • DEX treatment causes a marked reduction in the GR content of epididymal fat tissue.

  • No changes in NFκB and TLR-4 content is observed in parallel with GR downregulation.

  • Impaired insulin signaling occurs without pro inflammatory activation in adipose tissue from DEX rats.

Abstract

Objectives

Peripheral insulin resistance (IR) is one of the main side effects caused by glucocorticoid (GC)-based therapies, and the molecular mechanisms of GC-induced IR are not yet fully elucidated. Thus, we aimed to investigate the effects of dexamethasone treatment on the main components of insulin and inflammatory signaling in the adipose tissue of rats.

Materials/methods

Male Wistar rats received daily injections of dexamethasone (1 mg/kg body weight (b.w.), intraperitoneally (i.p.)) for 5 days (DEX), whereas control rats received saline (CTL). The metabolic status was investigated, and the epididymal fat fragments were collected for lipolysis and western blot analyses.

Results

The DEX rats became hyperglycemic, hyperinsulinemic, insulin resistant and glucose intolerant, compared with the CTL rats (P < 0.05). The basal glycerol release in the fat fragments was 1.5-fold higher in the DEX rats (P < 0.05). The phosphorylation of protein kinase B (PKB) at ser473 decreased by 44%, whereas, the phosphorylation of insulin receptor substrate (IRS)-1 at ser307 increased by 93% in the adipose tissue of the DEX rats after an oral bolus of glucose (P < 0.05). The basal phosphorylation of c-jun-N-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B (IKKβ) proteins was reduced by 46% and 58%, respectively, in the adipose tissue of the DEX rats (P < 0.05). This was paralleled with a significant reduction (47%) in the glucocorticoid receptor (GR) protein content in the adipose tissue of the DEX rats (P < 0.05).

Conclusion

The insulin-resistant status of rats induced by dexamethasone administration have PKB and IRS-1 activity attenuated in epididymal fat without increases in the phosphorylation of the proinflammatory signals JNK and IKKβ.

Introduction

Glucocorticoids (GCs) induce IR (insulin resistance) in peripheral tissues. In the adipose tissue, GCs increase lipolysis, while in the skeletal muscles and liver, GCs decrease the glucose uptake and increase the gluconeogenesis [1], [2]. These diabetogenic effects of GCs are exerted, at least in part, by antagonizing insulin actions [3], [4]. Insulin signaling is initiated upon insulin binding to its membrane receptor and the subsequent activation of intrinsic tyrosine kinase autophosphorylation that then leads to the phosphorylation of insulin receptor substrate (IRS)-1. The phosphorylated IRS-1 then activates the phosphatidylinositol 3-kinase (Pi3-kinase). Pi3-kinase seems to be the major mediator of protein kinase B (PKB) activation, which is essential for most of the physiological responses to insulin [5], [6], [7]. To become completely activated, PKB requires phosphorylation on two key residues, one on serine 473 and other on threonine 308 [8], [9]. These events result in glycogen synthesis and in the translocation of vesicles containing glucose transporter (GLUT)-4 to the cellular membrane for glucose uptake by skeletal muscles and fat cells [10], [11].

Proinflammatory proteins decrease insulin sensitivity by impairing the phosphorylation of proteins that participate in insulin signaling such as IRS-1 and PKB [12]. During obesity conditions, such as in metabolic syndrome (MS), there is an elevation in circulating proinflammatory cytokines, such as interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF), a process known as low-grade inflammation [13]. These cytokines may bind to specific receptors that result in the activation of protein kinases, including c-Jun-N-terminal kinase (JNK) and an inhibitor of the nuclear factor kappa-B (IKKβ) [14], [15]. These protein kinases activate the gene transcription of nuclear factor kappa B (NFκB) and activator protein 1 (AP1) [16], [17] and may also interfere negatively with insulin signaling by phosphorylating IRS-1 and decreasing PKB phosphorylation [18], [19]. In parallel, the released saturated fatty acids (SFA) during obesity may also bind to the receptors that trigger intracellular inflammatory signaling and may lead to subsequent impairment in insulin signaling [20]. This attenuation in insulin signaling is also associated with conditions of GC excess [3], [21]. Treatment with dexamethasone for up to 11 consecutive days promotes a reduction in PKB phosphorylation in the skeletal muscles [3] and decreases IRS-1 and PKB phosphorylation in the white adipose tissue of rats [21]. However, the mechanisms underlying GC-induced impairment in insulin signaling are not yet fully elucidated.

GCs exert their actions by binding to the glucocorticoid receptor (GR), which belongs to the nuclear receptor family, and act as the transcription factors [22], [23]. GR attenuates cellular inflammatory responses by suppressing the gene transcription of certain inflammatory components [24]. This GC-induced gene suppression occurs through the direct interaction of the GC–GR complex at glucocorticoid-responsive elements (GREs) and/or by protein–protein interactions of the GC–GR complex with NFkB or AP-1 signals [25], [26], [27]. When in excess, GCs may promote the downregulation of GR, as demonstrated after both in vitro and in vivo GC exposures [28]. However, whether adipose tissue is subjected to alleviated suppression of proinflammatory signaling concomitant with GR downregulation remains to be elucidated.

Dexamethasone-based therapies are routinely prescribed in clinical practice to treat several diseases based in their anti-inflammatory and immunosuppressive actions [29], [30]. Considering that the patients submitted to GC therapies develop peripheral IR and that there is an evidence that the GC exposure may lead to GR downregulation, we aimed to investigate whether there are any associations between insulin signaling attenuation and an alteration in proinflammatory signaling in the adipose tissue from GC-treated rats. We demonstrated that 5 days of dexamethasone administration in rats induced peripheral IR. These rats exhibited decreased PKB and increased IRS-1 phosphorylation at serine residues without increasing JNK and IKKβ phosphorylation in epididymal adipose tissue.

Section snippets

Ethical approval

The experiments with rats were approved by the Federal University of Santa Catarina Committee for Ethics in Animal Experimentation (approval ID: PP00782).

Materials

Dexamethasone phosphate (Decadron®) was purchased from Aché (Campinas, SP, Brazil). Human recombinant insulin (Humulin®) was from Lilly (Indianapolis, IN, USA). The reagents used in the glucose tolerance test, pyruvate tolerance test, and lipolysis and hepatic glycogen protocols were from LabSynth (Diadema, SP, Brazil) and Sigma (St. Louis,

Characteristics of the rats

There were no differences in the body weight between the CTL and DEX groups before the beginning of the treatment (Fig. 1A). The body weights were significantly reduced in the DEX rats after 48 h of dexamethasone administration and remained with a linear and sustained reduction until euthanasia. On the day of euthanasia, the body weight in the DEX group was 17% lower than that in the CTL group. The final body weights of the groups were 332 ± 11 and 275 ± 6 g for the CTL and for the DEX rats,

Discussion

In this study, we reproduced the well-established side effects of GC excess: reduced body weight and food intake [3], [21], [33], increased blood glucose levels, increased plasma insulin and triacylglycerol levels [3], [21], [33], [34], [46], increased hepatic glycogen content [33], [34], and reduced insulin sensitivity and glucose tolerance [21], [33], [34], [46]. In agreement with previous studies [3], [21], dexamethasone treatment resulted in the attenuation of insulin signaling in the

Authorship contributions

Participated in research design: Katia Motta and Alex Rafacho. Conducted experiments: Katia Motta, Amanda Marreiro Barbosa and Franciane Bobinski. Contributed analytic tools and data analysis: Katia Motta and Alex Rafacho. Performed data collection and interpretation: Katia Motta and Alex Rafacho. Contributed to manuscript writing: Katia Motta, Antonio Carlos Boschero and Alex Rafacho.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

This study was supported by grants from the CNPq (ID number 471397/2011-3). The authors appreciate the technical assistance of Cristiane dos Santos, Francielle BD Ferreira and Luiz Gonçalves-Neto and the kind donation of the ELISA kits by Dr. Adair R S Santos.

References (67)

  • H. Schacke et al.

    Mechanisms involved in the side effects of glucocorticoids

    Pharmacol. Ther.

    (2002)
  • F. Nagajyothi et al.

    Alterations in glucose homeostasis in a murine model of Chagas disease

    Am. J. Pathol.

    (2013)
  • M. Vaughan

    The production and release of glycerol by adipose tissue incubated in vitro

    J. Biol. Chem.

    (1962)
  • J.W. Jocken et al.

    Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity

    Physiol. Behav.

    (2008)
  • M. Franco-Colin et al.

    Effects of long-term high-sucrose and dexamethasone on fat depots, liver fat, and lipid fuel fluxes through the retroperitoneal adipose tissue and splanchnic area in rats

    Metabolism

    (2000)
  • B.G. Slavin et al.

    Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes

    J. Lipid Res.

    (1994)
  • D. Haasch et al.

    PKCtheta is a key player in the development of insulin resistance

    Biochem. Biophys. Res. Commun.

    (2006)
  • C. Wang et al.

    Protein kinase C q (PKCq)-dependent phosphorylation of PDK1 at Ser 504 and Ser 532 contributes to palmitate-induced insulin resistance

    J. Biol. Chem.

    (2009)
  • F. Svec et al.

    Glucocorticoids regulate the glucocorticoid receptor in the AtT-20Cell

    J. Biol. Chem.

    (1981)
  • S.F. Witchel et al.

    Mechanisms of disease: regulation of glucocorticoid and receptor levels – impact on the metabolic syndrome

    Nat. Clin. Pract. Endocrinol. Metab.

    (2006)
  • J. Burén et al.

    Dexamethasone impairs insulin signaling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes

    Eur. J. Endocrinol.

    (2002)
  • P.R. Shepherd

    Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues

    Acta Physiol. Scand.

    (2005)
  • P.J. Coffer et al.

    Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation

    Biochem. J.

    (1998)
  • M.A. Lawlor et al.

    PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?

    J. Cell Sci.

    (2001)
  • M.M. Chou et al.

    Regulation of protein kinase C zeta by PI 3-kinase and PDK-1

    Curr. Biol.

    (1998)
  • P. Cohen et al.

    PDKl, one of the missing links in insulin signal transduction?

    FEBS Lett.

    (2005)
  • A.R. Saltiel et al.

    Insulin signalling and the regulation of glucose and lipid metabolism

    Nature

    (2001)
  • D.M. Tsukumo et al.

    Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance

    Diabetes

    (2007)
  • A. Festa et al.

    The relation of body fat mass and distribution to markers of chronic inflammation

    Int. J. Obes. Relat. Metab. Disord.

    (2001)
  • M.C. Arkan et al.

    IKK-β links inflammation to obesity-induced insulin

    Nat. Med.

    (2005)
  • R. Medzhitov

    Toll-like receptors and innate immunity

    Nat. Rev. Immunol.

    (2001)
  • L.W. Chen et al.

    The two faces of IKK and NF-(B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion

    Nat. Med.

    (2003)
  • S.E. Hussey et al.

    TAK-242, a small molecule inhibitor of toll-like receptor-4 signaling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells

    Biosci. Rep.

    (2013)
  • Cited by (25)

    • Coadministration of sitagliptin or metformin has no major impact on the adverse metabolic outcomes induced by dexamethasone treatment in rats

      2021, Life Sciences
      Citation Excerpt :

      Aliquots of plasma were stored at −20 °C for further quantification of insulin by the AlphaLisa® system (PerkinElmer, Waltham, MA, USA, cat. N° AL204), active GLP-1 (Merck, EGLP-35 K), triacylglycerol, and total cholesterol (commercial kits from Biotécnica, Varginha, MG, Brazil) according to manufacturer's instructions and previous publications [16,22]. Please, see Table 1 for information about the sets of rats used in each case.

    View all citing articles on Scopus
    View full text